Drugs / Tongxinluo
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT04220372 | Jan 2020 → Jan 2021 | coronary microvascular disorder | Qilu Hospital of Shandong University | Unknown | No outcome recorded |
| Phase 4 | NCT03792035 | May 2019 → Sep 2021 | acute myocardial infarction | China National Center for Cardiovascular Diseases | Unknown | Met primary |
| Phase 4 | NCT01919671 | Mar 2014 → Oct 2016 | ischemic stroke | yongjun wang | Completed | Met primary |
| Phase 4 | NCT01721590 | Nov 2012 → May 2013 | coronary artery disorder | Han Yaling | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tongxinluo | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01919671 ↗ |
| Action | Inhibit | “tongxinluo's effectiveness in reducing the thrombin activity” NCT01721590 ↗ |
| Modality | Traditional medicine (herbal / TCM) | “Chinese patent drug” NCT01721590 ↗ |
| Route | Oral | “Participants received 4 oral capsules of Tongxinluo or placebo, 3 times a day for 90 days.” PMID 39325453 ↗ Sep 2024 |